SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
illustration of man entering into a painting, surreal virtual meta verse concept
Immuno-oncology
Cartography Pushes Sequencing to the Limit To Find Bananas in 100 Apples
The startup, launched out of CEO Kevin Parker’s grad school idyll during the COVID lockdowns, is primed to find new targets where Big Pharmas won’t dare.
October 15, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Digital illustration of the White House, a road leading to it, and a stars and stripes pattern in the sky.
Earnings
No Trump Drug Pricing Plan for J&J—Yet
Reporting third quarter earnings on Tuesday, Johnson & Johnson CEO Joaquin Duato said the healthcare giant has not yet secured a drug pricing deal with the White House, but discussions are ongoing.
October 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Robotic claw clutching a money stock illustration
Series B
Kailera Banks Massive $600M Raise for Phase III Obesity Study
Kailera’s lead asset, KAI-9531, elicited an average weight loss of more than 17% in a Phase III study in China. The biotech expects to launch a global late-stage program for the drug this year.
October 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Job Trends
Bonus Episode: Q3 2025 Job Market Update
In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q3 job market performance, layoffs and wider employment trends and policies impacting the biopharma workforce.
October 14, 2025
 · 
1 min read
 · 
Angela Gabriel
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Alzheimer’s disease
Roche, Lilly Win First FDA Nod for Alzheimer’s Blood Test for Primary Care Use
Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s Eisai-partnered Leqembi, with CEO Chris Viehbacher recently noting that such biomarker-based tests could “remove some of the bottlenecks” in uptake.
October 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Ultralight plane from bottom with blue wave on black. Illustration background, banner with copy space
Earnings
Thanks to Pfizer, Drug Pricing Clouds Begin To Clear as Q3 Earnings Roll Out
J&J reports today, just two weeks after Pfizer secured certainty on tariffs and drug pricing. Analysts expect to hear about plans from the rest of the industry during third period earnings calls.
October 14, 2025
 · 
5 min read
 · 
Annalee Armstrong
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says
Slapped with the most severe post-inspection classification, the state of Novo Nordisk’s Indiana manufacturing site could pose a problem for clients, including Regeneron and Scholar Rock.
October 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Deerfield - Circa June 2019: Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I
Artificial intelligence
Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline
Nabla and Takeda first joined hands in 2022, to push “the boundaries of next-generation biologics discovery,” according to the startup’s CEO Surge Biswas.
October 14, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Manufacturing
FDA’s PreCheck Proposal a Welcome but Insufficient Step, Company Execs Say
While a new facility setup program aimed at encouraging onshoring received a positive reception at a recent meeting, industry representatives said the current rules on existing production plants are the main regulatory issues facing manufacturing teams.
October 14, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS